Structure-guided, target-based drug discovery – exploiting genome information from HIV to mycobacterial infections
Postępy Biochemii · 2016
DOI: 10.18388/pb.2016_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Postępy Biochemii, 2016. Verfasst von Sony Malhotra und 3 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
The use of protein crystallography in structure-guided drug discovery allows identification of potential inhibitor-binding sites and optimisation of interactions of hits and lead compounds with a target protein. An early example of this approach was the use of the structure of HIV protease in designing AIDS antivirals. More recently, use of structure-guided design with fragment-based drug discovery, which reduces the size of screening libraries by decreasing complexity, has improved ligand efficiency in drug design. Here, we discuss the use of structure-guided target identification and lead optimisation using fragment-based approaches in the development of new antimicrobials for mycobacterial infections.
Zitieren
APA
Malhotra, S., Thomas, S. E., Montano, B. O., & Blundell, T. L. (2016). Structure-guided, target-based drug discovery – exploiting genome information from HIV to mycobacterial infections. Postępy Biochemii. https://doi.org/10.18388/pb.2016_25
Vancouver
Malhotra S, Thomas SE, Montano BO, Blundell TL. Structure-guided, target-based drug discovery – exploiting genome information from HIV to mycobacterial infections. Postępy Biochemii. 2016. doi:10.18388/pb.2016_25
BibTeX
@article{Malhotra2016,
author = {Malhotra, Sony and Thomas, Sherine E. and Montano, Bernardo Ochoa and Blundell, Tom L.},
title = {Structure-guided, target-based drug discovery – exploiting genome information from HIV to mycobacterial infections},
journal = {Postępy Biochemii},
year = {2016},
doi = {10.18388/pb.2016_25}
}
EUVIMED